Therefore, our aim is to check whether plasma levels of IGF-2, IGFBP-1, IGFBP-3, IGFBP-5 and IGFBP-7 might reflect changes between patients and controls, and also whether treatment with antidepressants (AD) may recover these levels and if they correlate with changes in subjective scales that measure depression severity (HDRS), anhedonia (SAAS), general cognitive state (MMSE) and memory (FCSRT). This evidence concerns the gene IGFBP5 and Alzheimer disease.